Trials / Completed
CompletedNCT01811576
Safety, Tolerability and Efficacy of Weekly TV-1106 in Adults With Growth Hormone Deficiency
A 64-Week (12-week Core Phase and 52-week Safety Extension), Phase II, Multicenter, Randomized, Open Label Study to Evaluate the Safety, Tolerability and Efficacy of Weekly TV-1106 in Adults With Growth Hormone Deficiency
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 52 (actual)
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc. · Industry
- Sex
- All
- Age
- 23 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to evaluate the clinical effect of TV-1106.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TV-1106 | |
| DRUG | Recombinant human growth hormone | Subcutaneous once daily |
Timeline
- Start date
- 2013-03-31
- Primary completion
- 2013-08-05
- Completion
- 2013-08-05
- First posted
- 2013-03-14
- Last updated
- 2021-12-10
Locations
23 sites across 9 countries: United States, Czechia, Germany, Greece, Hungary, Israel, Serbia, Slovakia, Slovenia
Source: ClinicalTrials.gov record NCT01811576. Inclusion in this directory is not an endorsement.